loading

Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari

Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
Data di fine periodo 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Durata del periodo 3 mesi 3 mesi 3 mesi 3 mesi 3 mesi
Revenues
90.80%
0.032
0.348 19.14 2.978 12.77
Operating Expenses
18.96%
66.01
55.49 54.78 71.90 56.00
Benefits Costs and Expenses
3.60%
74.95
72.35 36.51 42.51 104.95
Costs And Expenses
3.60%
74.95
72.35 36.51 42.51 104.95
Depreciation and Amortization
6.40%
0.133
0.125 0.107 0.113 -
Operating Income/Loss
19.65%
-65.98
-55.14 -35.63 -68.92 -43.23
Income/Loss From Continuing Operations Before Tax
4.05%
-74.92
-72.00 -17.36 -39.53 -92.18
Income/Loss From Continuing Operations After Tax
4.05%
-74.92
-72.00 -17.36 -39.53 -92.18
Net Income/Loss
4.05%
-74.92
-72.00 -17.36 -39.53 -92.18
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
99.56%
0.5198
119.00 118.56 116.12 1.6912
Diluted Average Shares
99.56%
0.5198
119.00 118.56 116.12 1.6912
Basic Earnings Per Share
3.28%
-0.63
-0.61 -0.15 -0.34 -0.95
Diluted Earnings Per Share
3.28%
-0.63
-0.61 -0.15 -0.34 -0.95
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$45.65
price down icon 0.48%
$28.06
price down icon 1.72%
$52.56
price down icon 1.55%
$91.19
price up icon 1.21%
$139.50
price down icon 0.01%
biotechnology ONC
$284.05
price down icon 0.44%
Capitalizzazione:     |  Volume (24 ore):